Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4 (CADL)

Summary by Seeking Alpha
Candel Therapeutics is upgraded to Strong Buy after phase 3 prostate cancer win; 30% lower recurrence supports 2026 BLA. Click for this CADL update.

1 Articles

Seeking AlphaSeeking Alpha
Lean Right

Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4 (CADL)

Candel Therapeutics is upgraded to Strong Buy after phase 3 prostate cancer win; 30% lower recurrence supports 2026 BLA. Click for this CADL update.

·Ra'anana, Israel
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Seeking Alpha broke the news in Ra'anana, Israel on Tuesday, September 22, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Needham icon

Needham

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal